Tissue Genesis, Inc
Honolulu, US
Tissue Genesis makes the Icellator2, an automated, enclosed system that isolates stromal vascular fraction (SVF) stem cells from adipose tissue in about an hour using its proprietary Adipase enzyme and single-use kits. The system targets clinics, operating rooms, and research labs, and is approved for clinical use in The Bahamas while under FDA IDE clinical studies in the USA.
BiotechHardwareMedical Devices
Founders & leadership
MR
Michael RuleyNamed on SEC filing
PK
Paul KosnikNamed on SEC filing
AC
Anton C KruckyNamed on SEC filing
RH
Robert HiamNamed on SEC filing
JW
Jeffrey WatanabeNamed on SEC filing
TC
Thomas CannonNamed on SEC filing
LR
Lawrence RodriguezNamed on SEC filing
AC
Anton C. KruckyNamed on SEC filing
TS
Timothy SarhattNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$8.2M disclosed across 2 rounds · 2011–2014
▶$500KraisedSep 2014 · 1 investors · BiotechnologyRule 506(b)
▶$500KraisedSep 2014 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lawrence RodriguezDirector
- Paul KosnikExecutive Officer
- Michael RuleyDirector
- Anton C. KruckyExecutive Officer, Director
- Robert HiamDirector
- Timothy SarhattDirector
- Thomas CannonExecutive Officer, Director
- Offering amount
- $6M
- Amount sold
- $500K
- Minimum investment
- $25K
- Proceeds to insiders
- $120K
- First sale
- Aug 2014
- Incorporated
- Corporation, Hawaii
- Federal exemptions
- 06b
▶$7.7MraisedJan 2012 · 53 investors · BiotechnologyRule 506(b)
▶$7.7MraisedJan 2012 · 53 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael RuleyDirector
- Paul KosnikExecutive Officer
- Anton C KruckyExecutive Officer, Director
- Robert HiamDirector
- Jeffrey WatanabeDirector
- Thomas CannonExecutive Officer, Director
- Offering amount
- $15.3M
- Amount sold
- $7.7M
- Minimum investment
- $10K
- First sale
- Dec 2011
- Incorporated
- Corporation, Hawaii
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity takenSource: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Tissue Genesis, Inc do?
- Tissue Genesis makes the Icellator2, an automated, enclosed system that isolates stromal vascular fraction (SVF) stem cells from adipose tissue in about an hour using its proprietary Adipase enzyme and single-use kits. The system targets clinics, operating rooms, and research labs, and is approved for clinical use in The Bahamas while under FDA IDE clinical studies in the USA.
- How much funding has Tissue Genesis, Inc raised?
- Tissue Genesis, Inc has disclosed $8.2M raised across 2 rounds.
- Where is Tissue Genesis, Inc headquartered?
- Tissue Genesis, Inc is headquartered in Honolulu, US.